Regular Article
The Human Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase Activating Peptide Receptor 1 (VPAC1): Constitutive Activation by Mutations at Threonine 343

https://doi.org/10.1006/bbrc.1998.9883Get rights and content

Abstract

The human vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor1 (VPAC1) belongs to the class II subfamily of G protein-coupled receptors. Specific changes by mutagenesis of a strictly conserved threonine (H) into lysine (K), proline (P) or alanine (A) at position 343 of the human VPAC1 receptor resulted in its constitutive activation with respect to cAMP production. Transfection of these mutants into Cos cells evoked a 3.5 fold-increase in the cAMP level as compared to cells transfected with the wild-type receptor. In contrast other mutants such as T343C, T343E or T343F were not constitutively activated. They were otherwise expressed at the cell surface of transfected nonpermeabilized cells. Double mutants were then constructed in which the T343K mutation was associated with a point mutation in the the N-terminal extracellular domain that totally abolished VIP binding or VIP-stimulated cAMP production i.e. E36A or D68A. The corresponding double mutants T343K-E36A and T343K-D68A were no longer constitutively activated. A control double mutant (T343K-D132A) with an unaltered dissociation constant for VIP and cAMP response to VIP, was still constitutively activated. Our findings demonstrate that constitutive activation of the VPAC1 receptor can be evoked by specific mutations of T343 at the junction of the second intracellular loop and fourth transmembrane segment. This constitutive activation appears to require the functional integrity of the N-terminal extracellular VIP binding domain.

References (25)

  • A.J. McKnight et al.

    Immunol. Today

    (1996)
  • V.G. Lelianova et al.

    J. Biol. Chem.

    (1997)
  • A. Couvineau et al.

    Biochem. Biophys. Res. Commun.

    (1995)
  • P. Gaudin et al.

    Biochem. Biophys. Res. Commun.

    (1995)
  • K. Du et al.

    Biochem. Biophys. Res. Commun.

    (1997)
  • A. Couvineau et al.

    J. Biol. Chem.

    (1996)
  • P. Gaudin et al.

    J. Biol. Chem.

    (1998)
  • M. Laburthe et al.

    J. Biol. Chem.

    (1987)
  • A. Couvineau et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • P.J. Munson et al.

    Anal. Biochem.

    (1980)
  • M.A. Kjelsberg et al.

    J. Biol. Chem.

    (1992)
  • C.C. Tseng et al.

    Biochem. Biophys. Res. Commun.

    (1997)
  • Cited by (16)

    • β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor

      2006, Journal of Biological Chemistry
      Citation Excerpt :

      These were the starting point for the rational design of the TYY mutant described below. Four of these were eliminated, because mutational data either: linked them to increased G protein activation (Leu-275) (23-26) or to decreased sequestration (Tyr-326) (27, 28) or was insufficient (Asn-330 and Ala-134). By contrast, the remaining three residues had mutations shown to decrease G protein signaling in multiple receptors and with no data suggesting a decrease in internalization.

    View all citing articles on Scopus

    Greeley, GH

    1

    To whom correspondence should be addressed. Fax: (33) 1 44 85 61 24. E-mail:[email protected].

    View full text